Osteosarcoma Research Portal logoOsteosarcoma Research Portal

Treatments and research

Three videos on the drugs used today, newer drugs in trials, and current research.

1. What the main treatment drugs do

This video explains what the main medicines used for osteosarcoma do.

For high-grade osteosarcoma, treatment combines chemotherapy and surgery. Chemotherapy is usually given before surgery to shrink the tumour, and after surgery to lower the chance of the cancer coming back.

In the UK, people under forty usually have a combination called MAP: high-dose methotrexate, doxorubicin and cisplatin. MAP is also the standard in national guidelines in the United States and China. People over forty, or those who cannot have high-dose methotrexate, may have doxorubicin and cisplatin without methotrexate.

Each medicine works in a different way. Methotrexate stops cells using folic acid to make and repair DNA. Doxorubicin blocks an enzyme that cells need to divide. Cisplatin damages cells that are dividing quickly. Combining medicines that act at different stages of cell division gives more chance of killing more cancer cells.

These medicines can cause side effects, so people are checked closely. High-dose methotrexate can affect the kidneys, so people have extra fluids, blood tests, and a medicine called folinic acid that reduces side effects. Doxorubicin can affect the heart, so people have heart scans. Cisplatin can affect the kidneys and hearing, so people have hearing tests and kidney checks.

Mifamurtide is not chemotherapy. It activates certain white blood cells. It is given after surgery, with chemotherapy, to people aged two to thirty whose cancer has not spread and has been removed. In a trial called INT-0133, of 678 patients, six-year survival rose from seventy to seventy-eight in every hundred. It is licensed in the European Union and recommended in the UK. It is not approved in the United States, and it is not approved in China.

If the tumour keeps growing during first treatment, ifosfamide and etoposide may be used. A large international trial, EURAMOS-1, added them to MAP for people whose tumours responded poorly. It did not lower the chance of the cancer coming back, and caused more side effects.

2. Newer drugs being tested

This video looks at newer medicines being tested for osteosarcoma that has come back, or has kept growing despite chemotherapy.

Most are tablets called kinase inhibitors. They block some of the signals that tumours use to grow and to form new blood vessels. None has been shown to cure osteosarcoma.

Regorafenib has the strongest evidence. In an American trial called SARC024, of adults aged eighteen to seventy-six, the cancer took a median of 3.6 months to grow again on regorafenib, against 1.7 months on a dummy pill. A French trial called REGOBONE also compared it with a dummy pill.

Cabozantinib works in a similar way. In a French trial called CABONE, that included people aged twelve and over, about one in three had no growth after six months, and about one in eight saw their tumours shrink.

Sorafenib was the first of these tablets to show activity in osteosarcoma, in an Italian trial. Adding a second medicine, everolimus, did not reach the trial's target, and two in three people needed lower doses or breaks.

Apatinib was tested in China in people aged sixteen and over. Tumours shrank in some people, but it was a small trial at one hospital, with no comparison group.

Lenvatinib was tested in an international trial called OLIE, of 81 people aged two to twenty-five, with chemotherapy. It did not show a clear benefit over chemotherapy alone.

None of these medicines is licensed for osteosarcoma in the UK, the United States, the European Union or China. They are licensed for other cancers. In the UK, they are not routinely available on the NHS for osteosarcoma, but may be given through compassionate access schemes. American and Chinese guidelines list some of them for relapse.

Immunotherapy has helped few people so far. In one trial of pembrolizumab, called SARC028, one of twenty-two people with osteosarcoma responded.

3. What the future looks like

This video looks at osteosarcoma research that is under way now. It separates what has been shown from what is still being tested.

Osteosarcoma can affect people of any age, so trials recruit different age groups. In the United States, a trial called AOST2032 is testing whether adding a tablet called cabozantinib to standard MAP chemotherapy helps people aged up to forty who have just been diagnosed. As of November 2026, the trial is suspended so that researchers can follow current patients for longer. Its result is not yet known.

In Europe, a large trial called FOSTER started recruiting people from the age of four. Its first new treatment is also cabozantinib.

Several immune treatments have been tested. In one trial of the immune medicine pembrolizumab, called SARC028, one of twenty-two people with osteosarcoma responded. In an early trial of immune cells altered in a laboratory to find a protein called HER2, no tumours shrank. Newer trials are testing medicines and immune cells aimed at proteins called B7-H3 and HER2. They have not reported results.

Osteosarcoma tumours have many changes in their genes, but few share the same change. Only some carry a change that an existing medicine is designed to act on. Whether matching treatment to these changes improves results has not been shown.

Tumours release small pieces of DNA into the blood. In one American study, finding this DNA at diagnosis was linked to worse outcomes. Whether it can be used to choose treatment is being tested.

Surgery has changed. In the United States, more than eighty in every hundred people with a tumour in an arm or leg can now keep the limb.

Research also follows people after treatment. In a large American study, about eight in every hundred survivors treated with MAP developed heart failure within twenty years.